Virtual Press Conference: FDA Clears AGT to Begin Phase 1 Clinical Trial of HIV Cure Program
Learn about AGT's HIV Cure Program in 1-Hour
Date: Thursday August 13, 1pm EST
Live Online | Media Only
What Will I Learn?
AGT is excited to announce its clearance by the FDA to begin a Phase I Trial for an HIV cure. Sign-up for this virtual press conference to learn the details of its program from AGT's Leadership.
The theory and history behind the therapy - AGT103-T autologous cell therapy
What is know so far - Pre-clinical results and peer reviewed publications
Clinical and patient details - Clinical sites, enrollment plan, and timelines
What Is It For?
Reporters and media.
The event has passed but here is a recording of the virtual press conference.
If you are interested in interviewing members of the company please contact us and we will reach out to you right away.
Meet the Speakers
Jeff Galvin
Chief Executive Officer
